Dalton Pharma Services has entered into a Manufacturing Services contract with Clarity Pharmaceutical.
Under the agreement Clarity’s PET based companion diagnostics and radio-immunotherapeutics development program will receive cGMP chemistry manufacturing,scale up and aseptic fill/finish services and analytical support from Dalton Pharma.
Dalton CEO Peter Pekos said,”Our expert capabilities in the manufacture of complex chemical products, including conjugation under sterile cGMP conditions and our strength in aseptic filling, solidified the manufacturing agreement.”
Clarity Pharmaceutical Managing Director Dr Matt Harris said,”Therapeutic targeting is one of the biggest opportunities for the advancement of novel treatments today.Clarity is pleased to launch this technology for use by the global pharmaceutical community.”
